The use of biomarkers GP-73 and AFP in the early diagnosis of hepatocarcinoma associated with liver cirrhosis of HCV etiology
https://doi.org/10.22625/2072-6732-2025-17-2-89-95
Abstract
Purpose: comparative study of the informativeness of tumor markers GP-73 and AFP in the early diagnosis of hepatocellular carcinoma associated with liver cirrhosis of HCV etiology.
Materials and methods: In the study, 71 people were divided into 4 groups. The groups included patients with hepatocarcinoma, liver cirrhosis, chronic viral hepatitis C and healthy people. Healthy people made up the comparison group. In all patients, the study included the study of AFP and GP-7 protein values. Fibrotic changes in the liver tissue were studied based on the results of ultrasound and fibroscanning of the liver using the Fibroscan apparatus (France).
Results. In the verification of fibrosis (cirrhosis) and tumor lesions of the liver, the threshold values for GP-73 and alpha-fetoprotein (AFP) were 529.9 ng/l and 29 ng/ml, respectively. At the same time, the level of specificity of the GP-73 marker was equal to 86%, and sensitivity – 87%. In this case, the sensitivity and specificity rates of AFP were 71% and 79%, respectively. The level of negative diagnostic value of the GP-73 marker was 86.5%, and the level of positive prognostic value of GP-73 was 85.2%, while these AFP indicators were 72.6% and 76%, respectively.
Conclusion: The marker – serum protein Golgi-73 can be used as a reliable diagnostic marker for early verification of hepatocellular carcinoma associated with liver cirrhosis of HCV etiology.
About the Authors
A. K. Bayjanov
Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
Uzbekistan
Uzbekistan
Tashkent
U. Yu. Ismоilov
Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
Uzbekistan
Uzbekistan
Tashkent
A. S. Khikmatullaeva
Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
Uzbekistan
Uzbekistan
Tashkent
Kh. P. Nasirova
Kimyo International University
Uzbekistan
Uzbekistan
Tashkent
J. A. Anvarov
Ташкентская медицинская академия
Uzbekistan
Uzbekistan
Tashkent
Ch. B. Turaeva
Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
Uzbekistan
Uzbekistan
Tashkent
References
1. Menshikov K.V., Sultanbaev A.V. Gepatotsellyulyarnaya karsinoma: etiologicheskie faktory i mexanizmy razvitiya. (obzor literatury) // Kreativnaya xirurgiya i onkologiya, – Tom 12. – № 2, 2022. – P. 139-150. (In Russ.)
2. Fudi CH. U., Yajun M.A. Clinical value of serum AFPL3 and GP73 in the diagnosis and assessment of primary liver cancer // Chinese Journal of Primary Medicine and Pharmacy, 2018:(12):3071-3074.
3. Rania A. El-Kady, Mohammed M. El-Naggar, Rehab A. Abd El-Shakour, Monir H. Bahgat. Utility of Alpha-FetoproteinL3 and Golgi Protein 73 for Diagnosis of Hepatocellular Carcinoma // Egyptian Journal of Medical Microbiology Volume 29 N 4 October, 2020:9-15/DOI: https://doi.org/10.51429/EJMM29402
4. Yujuan Liu, Jiyin Wang, Ruixiang Yang, Yuning Cheng, Yue Zhou, Hui Li, Wei Jiang & Xiaowei Zhang GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells // Oncogenesis, 2021;10:69. https://doi.org/10.1038/s41389-021-00358-3
5. Bayjanov A.K., Nasirova Kh.P. Significance of biomarkers of liver fibrosis and cirrhosis progression in chronic viral hepatitis C in patients with HIV infection / RA Journal of Applied Research Volume: 08 Issue: 07. July-2022 DOI: 10.47191/rajar/v8i7.10 http://www.rajournals.in/index.php/rajar/issue/view/178.
6. Fujiwara N., Friedman S.L., Goossens N., Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine // J Hepatol. 2018; 68(3):526e549. https://doi.org/10.1016/j.jhep.2017.09.016.
7. Farag R.A., Ayobi D., Alsaleh K.A., Kwon H.J., Ansary A. Studying the impact of Golgi protein 73 serving as a candidate biomarker in early diagnosis for hepatocellular carcinoma among Saudi patients // Asian Pac J Cancer Prev APJCP. 2019; 20(1):215e220 https://doi.org/10.31557/APJCP.2019.20.1.215.
8. Jiao C, Cui L, Piao J. Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma // J Canc Res Therapeut. 2018 Oct-Dec;14(6):1239e1244. https://doi.org/10.4103/0973-1482.199784. PMID: 30488837.
9. Khalil F.M., Negm S.I., Assal M.A. Serum level of Golgi protein-73 as a diagnostic marker for hepatocellular carcinoma // Benha Med J. 2018; 35:36e41.
10. Kimhofer T., Fye H., Robinson S., Thursz M., Holmes E. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review // Br J Canc. 2015; 112(7):1141e1156. https://doi.org/10.1038/bjc.2015.38.
11. Kulik L., Serag H. B. Epidemiology and management of hepatocellular carcinoma // Gastroenterology, 2019. – N 156 (2): – Р. 477-491. https://doi.org/10.1053/j.gastro.2018.08.065.471.
12. Llovet J.M., Kelley R.K., Villanueva A. Hepatocellular carcinoma // Nat Rev Dis Primers, 2021. – N7(1):6. DOI: 10.1038/s41572-020-00240-3.
13. Zhao S., Long M., Zhang X. The diagnostic value of the combination of Golgi protein 73, glypican-3 and AFP in hepatocellular carcinoma: a diagnostic metaanalysis. Ann Transl Med. 2020. Apr;8(8):536. https://doi.org/10.21037/atm. 2020.02.89. PMID: 32411759.PMCID: PMC7214882.
Review
For citations:
Bayjanov A.K., Ismоilov U.Yu., Khikmatullaeva A.S., Nasirova Kh.P., Anvarov J.A., Turaeva Ch.B. The use of biomarkers GP-73 and AFP in the early diagnosis of hepatocarcinoma associated with liver cirrhosis of HCV etiology. Journal Infectology. 2025;17(2):89-95. (In Russ.) https://doi.org/10.22625/2072-6732-2025-17-2-89-95
Views:
71
.png)
.png)
Email this article 